FOLH1 and neoplasm: Although this agent possesses a high and constant tumor uptake absolutely comparable to that of other reported [99mTc]Tc-PSMA-i inhibitors, it’s high uptake and long retention in the kidney constitute an important shortcoming that needs to be addressed.